<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04073368</url>
  </required_header>
  <id_info>
    <org_study_id>AXA1125-003</org_study_id>
    <nct_id>NCT04073368</nct_id>
  </id_info>
  <brief_title>Study of the Safety and Tolerability of AXA1125 and AXA1957 in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)</brief_title>
  <official_title>A 16-Week, Single-Blind Randomized, Placebo- Controlled Food Study of the Safety and Tolerability of AXA1125 and AXA1957 in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Axcella Health, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Axcella Health, Inc</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, single blind study to determine whether AXA1125 or AXA1957, novel&#xD;
      compositions of amino acids, are safe and well tolerated. Subjects have non-alcoholic fatty&#xD;
      liver disease (NAFLD) and the study will also examine liver biology using blood tests and&#xD;
      magnetic resonance imaging (MRI).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a 16-week, single-blind, randomized, placebo-controlled food study of the safety and&#xD;
      tolerability of AXA1125 and AXA1957 in subjects with NAFLD.&#xD;
&#xD;
      Subjects signed an informed consent form and were screened for eligibility, per the inclusion&#xD;
      and exclusion criteria below, up to 6 weeks before the start of the administration period.&#xD;
      Subjects were randomized as soon as eligibility was confirmed.&#xD;
&#xD;
      Eligible subjects were randomized in a 2:2:2:1 ratio to receive either AXA1125 24 g twice&#xD;
      daily (BID), AXA1957 20.3 g BID, AXA1957 13.5 g BID, or placebo 24 g BID. Randomization&#xD;
      occurred via an interactive web response system after eligibility was confirmed and&#xD;
      approximately 3 to 5 days prior to the Day 1 visit. Assigned study food product (AXA1125,&#xD;
      AXA1957, or placebo) were shipped to the study site upon randomization of each subject.&#xD;
&#xD;
      Once randomization had occurred, subjects presented to the study site on Day 1&#xD;
      (Baseline/Visit 2) for their baseline assessments per the schedule of events. Study Day 1 was&#xD;
      the beginning of the 16-week administration period.&#xD;
&#xD;
      Subjects returned to the study site at Week 1 (Visit 3), Week 2 (Visit 4), Week 4 (Visit 5),&#xD;
      Week 8 (Visit 6), Week 12 (Visit 7), and Week 16 (Visit 8) to receive their study food&#xD;
      product and/or to return any unused study food product, provide blood samples for biomarker&#xD;
      and other laboratory testing, undergo liver imaging, and complete other study safety&#xD;
      assessments per the schedule of events.&#xD;
&#xD;
      The Safety Follow-up Visit, which occurred approximately 2 weeks after the last visit in the&#xD;
      administration period (ie, after the Week 16 visit or at the time of early termination), was&#xD;
      the End of Study Visit (Visit 9).&#xD;
&#xD;
      There were 9 study visits in total, including the Screening and Follow-up Visits.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 3, 2018</start_date>
  <completion_date type="Actual">September 3, 2020</completion_date>
  <primary_completion_date type="Actual">March 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With Incidence of Study Product Emergent Adverse Events (AEs) and Any Serious Adverse Events (SAEs)</measure>
    <time_frame>Baseline to week 16</time_frame>
    <description>Subjects received AXA1125 at 24 g twice daily ( BID), AXA1957 at 20.3 g BID or 13.5 g BID with Product related AEs and any SAEs up to 16 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Liver Fat as Assessed by MRI- Proton Density Fat Fraction (PDFF)</measure>
    <time_frame>Baseline to week 16</time_frame>
    <description>Relative Changes From Baseline in MRI-PDFF at Week 16 in Overall Subjects (Safety Analysis Population)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)</measure>
    <time_frame>Baseline to week 16</time_frame>
    <description>Absolute Changes From Baseline in HOMA-IR at Week 16 in Overall Subjects (Safety Analysis Population)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Glucose Homeostasis</measure>
    <time_frame>Baseline to week 16</time_frame>
    <description>Absolute Changes From Baseline in HbA1c at Week 16 in Subjects with Diabetes (Safety Analysis Population)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative Change in Alanine Aminotransferase (ALT)</measure>
    <time_frame>Baseline to week 16</time_frame>
    <description>Relative Changes From Baseline in ALT at Week 16 in Overall Subjects (Safety Analysis Population)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Aspartate Aminotransferase (AST)</measure>
    <time_frame>Baseline to Week 16</time_frame>
    <description>Relative Changes From Baseline in AST at Week 16 in Overall Subjects (Safety Analysis Population)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">112</enrollment>
  <condition>NAFLD</condition>
  <arm_group>
    <arm_group_label>AXA1957 high dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AXA1957 20.3g</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AXA1957 low dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AXA1957 13.5g</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AXA1125</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AXA1125 24g</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 24g</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>AXA1957</intervention_name>
    <description>Amino acids, food study</description>
    <arm_group_label>AXA1957 high dose</arm_group_label>
    <arm_group_label>AXA1957 low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>AXA1125</intervention_name>
    <description>Amino acids, food study</description>
    <arm_group_label>AXA1125</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Amino acids, food study</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Willing to participate in the study and provide written informed consent.&#xD;
&#xD;
          -  Male and female adults aged &gt; 18 years.&#xD;
&#xD;
          -  Subjects must not have participated in any diet/lifestyle intervention or&#xD;
             observational studies, or engaged in any body weight altering regimens that resulted&#xD;
             in body weight fluctuations (i.e. body weight loss or gain by 5%) in the preceding 3&#xD;
             months prior to Screening.&#xD;
&#xD;
          -  A screening MRI consistent with liver inflammation and fibrosis.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Current or history of significant alcohol consumption.&#xD;
&#xD;
          -  History or presence of liver disease (other than NAFLD/NASH).&#xD;
&#xD;
          -  History or presence of cirrhosis and/or history or presence of hepatic decompensation.&#xD;
&#xD;
          -  Any diabetes other than Type 2.&#xD;
&#xD;
          -  Other poorly controlled medical condition (for example, uncontrolled hypertension with&#xD;
             a systolic blood pressure &gt; 100 mmHg).&#xD;
&#xD;
          -  Known sensitivity and/or history of clinically significant food intolerance/allergies&#xD;
             to proteins (including whey, soy, casein, amino acids, etc.).&#xD;
&#xD;
          -  Unable or unwilling to adhere to contraception requirements.&#xD;
&#xD;
          -  Any contraindications to a MRI scan.&#xD;
&#xD;
          -  Any other condition that, in the opinion of the Investigator, renders the subject at&#xD;
             risk for compliance, compromises the well-being of the subject, or hinders study&#xD;
             completion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Harrison, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pinnacle Clinical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Institute for Liver Health LLC</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Institute for Liver Health LLC</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85641</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Research Institute</name>
      <address>
        <city>Huntington Park</city>
        <state>California</state>
        <zip>90255</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Research Institute - Wilshire</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catalina Research Institute, LLC</name>
      <address>
        <city>Montclair</city>
        <state>California</state>
        <zip>91762</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Research Institute - Panorama</name>
      <address>
        <city>Panorama City</city>
        <state>California</state>
        <zip>91402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Excel Medical Clinical Trials, LLC</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33427</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Digestive Health Specialists</name>
      <address>
        <city>Lakewood Ranch</city>
        <state>Florida</state>
        <zip>34202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Compass Research, LLC - Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32789</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bioclinica Research</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Therapy and Advanced Research LLC</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City Research Institute</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastro One</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>20874</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pinnacle Clinical Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>73301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liver Center of Texas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Doctors Hospital at Renaissance, LLC</name>
      <address>
        <city>Edinburg</city>
        <state>Texas</state>
        <zip>78504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Digestive Disease Consultants (TDDC) - Downtown Fort Worth</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pinnacle Clinical Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>August 27, 2019</study_first_submitted>
  <study_first_submitted_qc>August 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 29, 2019</study_first_posted>
  <results_first_submitted>June 8, 2021</results_first_submitted>
  <results_first_submitted_qc>June 30, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 2, 2021</results_first_posted>
  <last_update_submitted>July 1, 2021</last_update_submitted>
  <last_update_submitted_qc>July 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 1, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/68/NCT04073368/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 9, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/68/NCT04073368/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>112 subjects signed consent and randomized. Ten subjects screen failed prior to day 1 dosing ( after signing consent) and the number of participants who started the study is 102 subjects.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>AXA1957 High Dose</title>
          <description>AXA1957 20.3g&#xD;
AXA1957: Amino acids, food study</description>
        </group>
        <group group_id="P2">
          <title>AXA1957 Low Dose</title>
          <description>AXA1957 13.5g&#xD;
AXA1957: Amino acids, food study</description>
        </group>
        <group group_id="P3">
          <title>AXA1125</title>
          <description>AXA1125 24g&#xD;
AXA1125: Amino acids, food study</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Placebo 24g&#xD;
Placebo: Amino acids, food study</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="29"/>
                <participants group_id="P4" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="26"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject noncompliance</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>This is the safety analysis population</population>
      <group_list>
        <group group_id="B1">
          <title>AXA1957 High Dose</title>
          <description>AXA1957 20.3g&#xD;
AXA1957: Amino acids, food study</description>
        </group>
        <group group_id="B2">
          <title>AXA1957 Low Dose</title>
          <description>AXA1957 13.5g&#xD;
AXA1957: Amino acids, food study</description>
        </group>
        <group group_id="B3">
          <title>AXA1125</title>
          <description>AXA1125 24g&#xD;
AXA1125: Amino acids, food study</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Placebo 24g&#xD;
Placebo: Amino acids, food study</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
            <count group_id="B2" value="26"/>
            <count group_id="B3" value="29"/>
            <count group_id="B4" value="15"/>
            <count group_id="B5" value="102"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.1" spread="12.79"/>
                    <measurement group_id="B2" value="49.6" spread="10.74"/>
                    <measurement group_id="B3" value="49.2" spread="12.79"/>
                    <measurement group_id="B4" value="53.2" spread="9.62"/>
                    <measurement group_id="B5" value="50.2" spread="11.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="62"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="95"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Type 2 diabetes mellitus status (T2DM)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Incidence of Study Product Emergent Adverse Events (AEs) and Any Serious Adverse Events (SAEs)</title>
        <description>Subjects received AXA1125 at 24 g twice daily ( BID), AXA1957 at 20.3 g BID or 13.5 g BID with Product related AEs and any SAEs up to 16 weeks</description>
        <time_frame>Baseline to week 16</time_frame>
        <population>Subjects received AXA1125 at 24 g BID, AXA1957 at 20.3 g BID or 13.5 g BID, or placebo for up to 16 weeks.</population>
        <group_list>
          <group group_id="O1">
            <title>AXA1957 High Dose</title>
            <description>AXA1957 20.3g&#xD;
AXA1957: Amino acids, food study</description>
          </group>
          <group group_id="O2">
            <title>AXA1957 Low Dose</title>
            <description>AXA1957 13.5g&#xD;
AXA1957: Amino acids, food study</description>
          </group>
          <group group_id="O3">
            <title>AXA1125</title>
            <description>AXA1125 24g&#xD;
AXA1125: Amino acids, food study</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo 24g&#xD;
Placebo: Amino acids, food study</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Incidence of Study Product Emergent Adverse Events (AEs) and Any Serious Adverse Events (SAEs)</title>
          <description>Subjects received AXA1125 at 24 g twice daily ( BID), AXA1957 at 20.3 g BID or 13.5 g BID with Product related AEs and any SAEs up to 16 weeks</description>
          <population>Subjects received AXA1125 at 24 g BID, AXA1957 at 20.3 g BID or 13.5 g BID, or placebo for up to 16 weeks.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Product Related Product-Emergent AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Liver Fat as Assessed by MRI- Proton Density Fat Fraction (PDFF)</title>
        <description>Relative Changes From Baseline in MRI-PDFF at Week 16 in Overall Subjects (Safety Analysis Population)</description>
        <time_frame>Baseline to week 16</time_frame>
        <population>Relative Changes From Baseline in MRI-PDFF at Week 16 in Overall Subjects (Safety Analysis Population)</population>
        <group_list>
          <group group_id="O1">
            <title>AXA1957 High Dose</title>
            <description>AXA1957 20.3g&#xD;
AXA1957: Amino acids, food study</description>
          </group>
          <group group_id="O2">
            <title>AXA1957 Low Dose</title>
            <description>AXA1957 13.5g&#xD;
AXA1957: Amino acids, food study</description>
          </group>
          <group group_id="O3">
            <title>AXA1125</title>
            <description>AXA1125 24g&#xD;
AXA1125: Amino acids, food study</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo 24g&#xD;
Placebo: Amino acids, food study</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Liver Fat as Assessed by MRI- Proton Density Fat Fraction (PDFF)</title>
          <description>Relative Changes From Baseline in MRI-PDFF at Week 16 in Overall Subjects (Safety Analysis Population)</description>
          <population>Relative Changes From Baseline in MRI-PDFF at Week 16 in Overall Subjects (Safety Analysis Population)</population>
          <units>percentage of change of MRI_PDFF</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.12" spread="24.904"/>
                    <measurement group_id="O2" value="-20.29" spread="23.064"/>
                    <measurement group_id="O3" value="-22.88" spread="23.040"/>
                    <measurement group_id="O4" value="-5.74" spread="20.425"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)</title>
        <description>Absolute Changes From Baseline in HOMA-IR at Week 16 in Overall Subjects (Safety Analysis Population)</description>
        <time_frame>Baseline to week 16</time_frame>
        <population>Absolute Changes From Baseline in HOMA-IR at Week 16 in Overall Subjects (Safety Analysis Population)</population>
        <group_list>
          <group group_id="O1">
            <title>AXA1957 High Dose</title>
            <description>AXA1957 20.3g&#xD;
AXA1957: Amino acids, food study</description>
          </group>
          <group group_id="O2">
            <title>AXA1957 Low Dose</title>
            <description>AXA1957 13.5g&#xD;
AXA1957: Amino acids, food study</description>
          </group>
          <group group_id="O3">
            <title>AXA1125</title>
            <description>AXA1125 24g&#xD;
AXA1125: Amino acids, food study</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo 24g&#xD;
Placebo: Amino acids, food study</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)</title>
          <description>Absolute Changes From Baseline in HOMA-IR at Week 16 in Overall Subjects (Safety Analysis Population)</description>
          <population>Absolute Changes From Baseline in HOMA-IR at Week 16 in Overall Subjects (Safety Analysis Population)</population>
          <units>percentage of change of HOM-IR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.421" spread="34.5866"/>
                    <measurement group_id="O2" value="1.445" spread="3.6396"/>
                    <measurement group_id="O3" value="-4.369" spread="16.8680"/>
                    <measurement group_id="O4" value="0.720" spread="4.7074"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Glucose Homeostasis</title>
        <description>Absolute Changes From Baseline in HbA1c at Week 16 in Subjects with Diabetes (Safety Analysis Population)</description>
        <time_frame>Baseline to week 16</time_frame>
        <population>Absolute Changes From Baseline in HbA1c at Week 16 in Subjects with Diabetes (Safety Analysis Population)</population>
        <group_list>
          <group group_id="O1">
            <title>AXA1957 High Dose</title>
            <description>AXA1957 20.3g&#xD;
AXA1957: Amino acids, food study</description>
          </group>
          <group group_id="O2">
            <title>AXA1957 Low Dose</title>
            <description>AXA1957 13.5g&#xD;
AXA1957: Amino acids, food study</description>
          </group>
          <group group_id="O3">
            <title>AXA1125</title>
            <description>AXA1125 24g&#xD;
AXA1125: Amino acids, food study</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo 24g&#xD;
Placebo: Amino acids, food study</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Glucose Homeostasis</title>
          <description>Absolute Changes From Baseline in HbA1c at Week 16 in Subjects with Diabetes (Safety Analysis Population)</description>
          <population>Absolute Changes From Baseline in HbA1c at Week 16 in Subjects with Diabetes (Safety Analysis Population)</population>
          <units>change in HbA1c</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0138" spread="0.01419"/>
                    <measurement group_id="O2" value=".0001" spread="0.00588"/>
                    <measurement group_id="O3" value="-0.0070" spread="8.008"/>
                    <measurement group_id="O4" value="-0.0027" spread="0.00874"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relative Change in Alanine Aminotransferase (ALT)</title>
        <description>Relative Changes From Baseline in ALT at Week 16 in Overall Subjects (Safety Analysis Population)</description>
        <time_frame>Baseline to week 16</time_frame>
        <population>Relative Changes From Baseline in ALT at Week 16 in Overall Subjects (Safety Analysis Population)</population>
        <group_list>
          <group group_id="O1">
            <title>AXA1957 High Dose</title>
            <description>AXA1957 20.3g&#xD;
AXA1957: Amino acids, food study</description>
          </group>
          <group group_id="O2">
            <title>AXA1957 Low Dose</title>
            <description>AXA1957 13.5g&#xD;
AXA1957: Amino acids, food study</description>
          </group>
          <group group_id="O3">
            <title>AXA1125</title>
            <description>AXA1125 24g&#xD;
AXA1125: Amino acids, food study</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo 24g&#xD;
Placebo: Amino acids, food study</description>
          </group>
        </group_list>
        <measure>
          <title>Relative Change in Alanine Aminotransferase (ALT)</title>
          <description>Relative Changes From Baseline in ALT at Week 16 in Overall Subjects (Safety Analysis Population)</description>
          <population>Relative Changes From Baseline in ALT at Week 16 in Overall Subjects (Safety Analysis Population)</population>
          <units>percentage change of ALT</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.65" spread="30.163"/>
                    <measurement group_id="O2" value="-19.19" spread="30.559"/>
                    <measurement group_id="O3" value="-21.86" spread="25.991"/>
                    <measurement group_id="O4" value="-7.20" spread="36.483"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Aspartate Aminotransferase (AST)</title>
        <description>Relative Changes From Baseline in AST at Week 16 in Overall Subjects (Safety Analysis Population)</description>
        <time_frame>Baseline to Week 16</time_frame>
        <population>Relative Changes From Baseline in AST at Week 16 in Overall Subjects (Safety Analysis Population)</population>
        <group_list>
          <group group_id="O1">
            <title>AXA1957 High Dose</title>
            <description>AXA1957 20.3g&#xD;
AXA1957: Amino acids, food study</description>
          </group>
          <group group_id="O2">
            <title>AXA1957 Low Dose</title>
            <description>AXA1957 13.5g&#xD;
AXA1957: Amino acids, food study</description>
          </group>
          <group group_id="O3">
            <title>AXA1125</title>
            <description>AXA1125 24g&#xD;
AXA1125: Amino acids, food study</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo 24g&#xD;
Placebo: Amino acids, food study</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Aspartate Aminotransferase (AST)</title>
          <description>Relative Changes From Baseline in AST at Week 16 in Overall Subjects (Safety Analysis Population)</description>
          <population>Relative Changes From Baseline in AST at Week 16 in Overall Subjects (Safety Analysis Population)</population>
          <units>percentage of AST from basline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.40" spread="30.898"/>
                    <measurement group_id="O2" value="-17.02" spread="30.898"/>
                    <measurement group_id="O3" value="-16.76" spread="27.908"/>
                    <measurement group_id="O4" value="-7.49" spread="40.499"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the time of informed consent up to first administration of study product on Day 1, any untoward medical occurrence considered related to study procedures will be recorded as an AE. Adverse events that occur from the first administration of study product on Day 1 through the Follow-up Visit / Week 18 will be considered treatment-emergent AEs</time_frame>
      <group_list>
        <group group_id="E1">
          <title>AXA1957 High Dose</title>
          <description>AXA1957 20.3g&#xD;
AXA1957: Amino acids, food study</description>
        </group>
        <group group_id="E2">
          <title>AXA1957 Low Dose</title>
          <description>AXA1957 13.5g&#xD;
AXA1957: Amino acids, food study</description>
        </group>
        <group group_id="E3">
          <title>AXA1125</title>
          <description>AXA1125 24g&#xD;
AXA1125: Amino acids, food study</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Placebo 24g&#xD;
Placebo: Amino acids, food study</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>laryngeal squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Margaret Koziel, MD</name_or_title>
      <organization>Axcella Health, Inc</organization>
      <phone>8573202200</phone>
      <email>clinicaltrials@axcellahealth.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

